Madrigal Transitions CMO Role as MASH Leadership Evolves

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced that its founder and longtime Chief Medical Officer, Dr. Rebecca Taub, will transition to the role of Senior Scientific and Medical Advisor while continuing to serve on the company’s Board of Directors. Dr. David Soergel will succeed her as Executive Vice President and Chief Medical Officer, effective April 21, 2025.

Dr. Taub, who co-founded Madrigal in 2011 after a distinguished academic and industry career, played a pivotal role in the development of Rezdiffra™ (resmetirom), the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH). Under her leadership, the company grew from a small R&D team into a commercial-stage biopharma with over 500 employees across the U.S. and Europe.

CEO Bill Sibold praised Dr. Taub’s groundbreaking work, noting her legacy as a scientist and entrepreneur who brought hope to patients with previously untreatable liver disease. “Her story is one of visionary leadership that will continue to inspire the biopharma community,” said Sibold.

Dr. Soergel brings over 20 years of clinical development experience, most recently serving as EVP and Global Head of Cardiovascular, Renal, and Metabolism Development at Novartis. There, he oversaw major drug programs and played key roles in the approvals of Leqvio, Fabhalta, and Vanrafia. He also contributed to the strategic acquisitions of the Medicines Company and Chinook Therapeutics. Dr. Soergel began his career in translational medicine at GlaxoSmithKline and trained in pediatrics and cardiology at Johns Hopkins and CHOP.

Commenting on his new role, Dr. Soergel expressed enthusiasm for building on Madrigal’s scientific foundation and advancing its leadership in MASH. “It’s a privilege to follow in Becky’s footsteps and join a team that has already delivered a historic first in drug development,” he said. “With two fully enrolled outcomes studies for Rezdiffra underway, we’re poised for continued innovation and growth.”